Protalix BioTherapeutics (PLX) EBIT (2010 - 2026)
Protalix BioTherapeutics' quarterly EBIT came in at $21.1 million in Q1 2026, up 610.16% year-on-year from $3.0 million in Q1 2025, and up 6393.45% quarter-over-quarter from -$336000.0 in Q4 2025.
Protalix BioTherapeutics has reported EBIT for 17 years, with the latest figure at $21.1 million in Q1 2026.
- For the quarter ending Q1 2026, EBIT rose 610.16% year-over-year to $21.1 million; the trailing twelve-month figure through Mar 2026 stood at $24.1 million (up 421.02% YoY), and the FY2025 full-year result was -$1.2 million, down 130.07% from the prior year.
- EBIT for Q1 2026 stood at $21.1 million, up from -$336000.0 in the prior quarter.
- The five-year high for EBIT was $21.1 million in Q1 2026, with the low at -$5.6 million in Q4 2023.
- Average EBIT over 5 years is $1.8 million, with a median of -$1.9 million recorded in 2022.
- Year-over-year, EBIT tumbled 174.91% in 2023 and soared 610.16% in 2026.
- Tracing PLX's EBIT over 5 years: stood at $7.5 million in 2022, then plunged by 174.91% to -$5.6 million in 2023, then surged by 228.39% to $7.2 million in 2024, then sank by 104.66% to -$336000.0 in 2025, then jumped by 6393.45% to $21.1 million in 2026.
- The last three EBIT figures came in at $21.1 million (Q1 2026), -$336000.0 (Q4 2025), and $2.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn | 21.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.15 Mn |
| Dec 31, 2025 | -336,000.00 |
| Sep 30, 2025 | 2.13 Mn |
| Jun 30, 2025 | 1.17 Mn |
| Mar 31, 2025 | -4.15 Mn |
| Dec 31, 2024 | 7.21 Mn |
| Sep 30, 2024 | 3.99 Mn |
| Jun 30, 2024 | -2.43 Mn |
| Mar 31, 2024 | -4.86 Mn |
| Dec 31, 2023 | -5.62 Mn |
| Sep 30, 2023 | -1.89 Mn |
| Jun 30, 2023 | 20.42 Mn |
| Mar 31, 2023 | -2.46 Mn |
| Dec 31, 2022 | 7.50 Mn |
| Sep 30, 2022 | -3.13 Mn |
| Jun 30, 2022 | -5.52 Mn |
| Mar 31, 2022 | -1.87 Mn |
| Dec 31, 2021 | -5.71 Mn |
| Sep 30, 2021 | -1.89 Mn |
| Jun 30, 2021 | -9.17 Mn |
| Mar 31, 2021 | -3.71 Mn |
| Dec 31, 2020 | 2.84 Mn |
| Sep 30, 2020 | -2.58 Mn |
| Jun 30, 2020 | -2.24 Mn |
| Mar 31, 2020 | 4.69 Mn |
| Dec 31, 2019 | 2.20 Mn |
| Sep 30, 2019 | -1.54 Mn |
| Jun 30, 2019 | -5.84 Mn |
| Mar 31, 2019 | -5.53 Mn |
| Dec 31, 2018 | -3.67 Mn |
| Sep 30, 2018 | -3.74 Mn |
| Jun 30, 2018 | -6.74 Mn |
| Mar 31, 2018 | -5.15 Mn |
| Dec 31, 2017 | -9.58 Mn |
| Sep 30, 2017 | -7.77 Mn |
| Jun 30, 2017 | -10.81 Mn |
| Mar 31, 2017 | -6.37 Mn |
| Dec 31, 2016 | -8.72 Mn |
| Sep 30, 2016 | -6.65 Mn |
| Jun 30, 2016 | -9.93 Mn |
| Mar 31, 2016 | -7.86 Mn |
| Dec 31, 2015 | -7.70 Mn |
| Sep 30, 2015 | -5.00 Mn |
| Jun 30, 2015 | -5.58 Mn |
| Mar 31, 2015 | -5.38 Mn |
| Mar 31, 2014 | -6.47 Mn |
| Dec 31, 2013 | -17.10 Mn |
| Sep 30, 2013 | -5.65 Mn |
| Jun 30, 2013 | -6.89 Mn |
| Mar 31, 2013 | -4.43 Mn |
| Dec 31, 2012 | -10.17 Mn |
| Sep 30, 2012 | -5.56 Mn |
| Jun 30, 2012 | 9.62 Mn |
| Mar 31, 2012 | -6.07 Mn |
| Dec 31, 2011 | -8.86 Mn |
| Sep 30, 2011 | -8.77 Mn |
| Jun 30, 2011 | -13.87 Mn |
| Mar 31, 2011 | -5.04 Mn |
| Dec 31, 2010 | -8.85 Mn |
| Sep 30, 2010 | -2.85 Mn |
| Jun 30, 2010 | -10.15 Mn |